CN Patent

CN106967074A — Cdk抑制剂

Assigned to G1 Therapeutics Inc · Expires 2017-07-21 · 9y expired

What this patent protects

式I、II或III的化合物及其药学可接受盐用作CDK抑制剂

USPTO Abstract

式I、II或III的化合物及其药学可接受盐用作CDK抑制剂

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN106967074A
Jurisdiction: CN
Classification: —
Expires: 2017-07-21
Drug substance claim: No
Drug product claim: No
Assignee: G1 Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.